早产儿出生后立即过渡期脑组织氧饱和度指导氧输送(COSGOD III):一项研究者发起的随机多中心多国临床试验,比较附加脑组织氧饱和度监测联合既定治疗指南与标准监测及常规治疗
COSGOD III为研究者发起的随机多中心多国III期临床试验,纳入胎龄小于32周的早产儿,比较出生后最初15分钟内附加脑组织氧饱和度(crSO2)监测联合既定治疗指南与仅常规监测SpO2和心率对主要结局(死亡或脑损伤)的影响。研究假设附加crSO2监测可能提高无脑损伤存活率,试验注册号NCT03166722,注册日期2017年3月5日。
要点
- COSGOD III为III期随机多中心多国临床试验,针对胎龄小于32周早产儿出生后立即过渡期。
- 研究组可见crSO2、SpO2和HR并按既定治疗指南干预,对照组仅可见SpO2和HR并接受常规治疗。
- 主要结局为死亡或脑损伤(脑室内出血或囊性脑室周围白质软化或两者兼有)。
核心结论
- 附加crSO2监测联合既定治疗指南可能提高早产儿无脑损伤存活率,但尚需试验验证。
- 原文指出crSO2监测在立即过渡期已被证明可行并能改善脑氧合。
研究设计与样本
- COSGOD III为研究者发起的随机多中心多国III期临床试验。
- 纳入胎龄小于32周、决定提供全力生命支持并获父母知情同意的早产儿。
- 排除严重脑、心、肺先天畸形或产前脑损伤或两者兼有者。
- 早产儿随机分为研究组和对照组,两组出生后立即放置近红外光谱(NIRS)设备(左前额)、脉搏血氧仪(右手掌/腕)和心电图。
主要发现
- 研究组可见crSO2、SpO2和HR读数,并按既定治疗指南接受治疗。
- 对照组仅可见SpO2和HR,接受常规治疗。
- 干预持续至出生后最初15分钟(立即过渡期和复苏期间),此后每例新生儿随访至主要结局(至矫正胎龄日期或出院)。
- 主要结局为死亡或脑损伤(定义为任何脑室内出血或囊性脑室周围白质软化或两者兼有)。
- 次要结局为新生儿发病率。
关键数值与推荐
- 主要结局:死亡或脑损伤(脑室内出血或囊性脑室周围白质软化或两者兼有)。
- 干预时长:出生后最初15分钟。
- 试验注册号:ClinicalTrials.gov Identifier: NCT03166722,注册日期2017年3月5日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transition immediately after birth is a complex physiological process. The neonate has to establish sufficient ventilation to ensure significant changes from intra-uterine to extra-uterine circulation. If hypoxia or bradycardia or both occur, as commonly happens during immediate transition in preterm neonates, cerebral hypoxia-ischemia may cause perinatal brain injury. The primary objective of the COSGOD phase III trial is to investigate whether it is possible to increase survival without cerebral injury in preterm neonates of less than 32 weeks of gestation by targeting cerebral tissue oxygen saturation (crSO2) using specified clinical treatment guidelines during the immediate transition period after birth (the first 15 min) in addition to the routine monitoring of arterial oxygen saturation (SpO2) and heart rate (HR). METHODS/DESIGN: COSGOD III is an investigator-initiated, randomized, multi-center, multi-national, phase III clinical trial. Inclusion criteria are neonates of less than 32 weeks of gestation, decision to provide full life support, and parental informed consent. Exclusion criteria are severe congenital malformations of brain, heart, lung, or prenatal cerebral injury or a combination of these. The premature infants will be randomly assigned to study or control groups. Both groups will have a near-infrared spectroscopy (NIRS) device (left frontal), pulse oximeter (right palm/wrist), and electrocardiogram placed immediately after birth. In the study group, the crSO2, SpO2, and HR readings are visible, and the infant will receive treatment in accordance with defined treatment guidelines. In the control group, only SpO2 and HR will be visible, and the infant will receive routine treatment. The intervention period will last for the first 15 min after birth during the immediate transition period and resuscitation. Thereafter, each neonate will be followed up for primary outcome to term date or discharge. The primary outcome is mortality or cerebral injury (or both) defined as any intra-ventricular bleeding or cystic periventricular leukomalacia (or both). Secondary outcomes are neonatal morbidities. DISCUSSION: crSO2 monitoring during immediate transition has been proven to be feasible and improve cerebral oxygenation during immediate transition. The additional monitoring of crSO2 with dedicated interventions may improve outcome of preterm neonates as evidenced by increased survival without cerebral injury. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03166722 . Registered March 5, 2017.
引用
- Pichler G, Baumgartner S, Biermayr M, et al. Cerebral regional tissue Oxygen Saturation to Guide Oxygen Delivery in preterm neonates during immediate transition after birth (COSGOD III): an investigator-initiated, randomized, multi-center, multi-national, clinical trial on additional cerebral tissue oxygen saturation monitoring combined with defined treatment guidelines versus standard monitoring and treatment as usual in premature infants during immediate transition: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30894226. doi:10.1186/s13063-019-3258-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。